MK-677: the ghrelin mimetic you can swallow

Ibutamoren is the name. MK-677 is the lab code Merck used, and it is the name that stuck. It is not a peptide. A peptide is a chain of amino acids a gut protease can cut, which is why ipamorelin and CJC are injected if you want them to arrive. Ibutamoren is a small spiropiperidine, built to survive the stomach and the liver and still fit the ghrelin receptor, GHS-R1a. You swallow it. That single fact is most of its reputation. The receptor it occupies is the same one ghrelin uses and the same one ipamorelin uses. The clock is the difference. A peptide secretagogue is gone in well under an hour. Ibutamoren hangs around for hours, so one dose a day keeps tickling the receptor across meals, sleep and the next morning.

In short. MK-677 is a pill-shaped chemical, not a peptide. It presses the same receptor as ghrelin and ipamorelin, and it lasts for hours instead of minutes.

What the receptor does has not changed because the ligand is oral. On the somatotroph, GHS-R1a raises calcium and, together with the GHRH signal, empties growth-hormone granules. In the arcuate nucleus the same receptor sits on NPY and AgRP neurons, which is why ghrelin makes you hungry and why ibutamoren makes you hungry. Hunger is not a side effect that a clever dose avoids. It is the receptor, doing the other job it evolved to do. Chapman, in the Journal of Clinical Endocrinology and Metabolism in 1996, gave it daily to older adults and watched growth hormone and IGF-1 rise. Nass, Annals of Internal Medicine, 2008, ran a longer trial in healthy older people: IGF-1 moved back toward a younger range, appetite went up, and fat-free mass ticked up. Fat-free mass on a scan includes water. Growth hormone retains water. Read the scan with that in mind.

In short. It raises growth hormone and IGF-1, and it makes you hungry, because both of those are what the ghrelin receptor is for. Some of the weight is water.

The pituitary likes growth hormone in pulses. A trough is not wasted time. It is how the liver's STAT5 programme stays a programme rather than a continuous shout, and it is one reason acromegaly looks the way it looks when a tumour never lets the signal fall. Ipamorelin, and CJC without DAC, are short on purpose. They amplify a pulse and then get out of the way. Ibutamoren's hours-long life means the ghrelin side of that conversation stays partly on between meals. The papers still show pulsatile growth hormone, not a flat line, but the baseline of the conversation is higher for more of the clock. That is useful if your question is an older adult with a sleepy axis and a low IGF-1. It is a different object from a short peptide you wanted for a single large pulse. IGF-1, being the integral, rises either way. The shape of the day underneath it does not.

In short. Short peptides make a pulse and leave. MK-677 stays for hours, so the axis is nudged all day. IGF-1 still rises. The shape of the day is not the same.

Insulin hears this. Growth hormone makes fat cells release fatty acids and makes the liver and muscle a little deaf to insulin. In the Nass trial and in the studies around it, fasting glucose drifted up and insulin sensitivity drifted down. For an older person who was already sliding toward diabetes, that drift is the bill that matters more than the IGF-1. For a lean lifter eating a surplus, it is water, hunger, and a glucose number worth watching rather than a free recomposition. Cortisol and prolactin move less than they do with GHRP-6, which is why people file MK-677 as clean. Less is not none, and hunger is not optional. Calling it a SARM is a category error. SARMs bind the androgen receptor. Ibutamoren never goes near it. You will not get androgenic hair loss from the ghrelin receptor. You might get hungry enough to undo the cut you thought you were on.

In short. Blood sugar often creeps up, because growth hormone fights insulin. It is not a SARM and it will not touch your hair through the androgen receptor. It will make you eat.

If the question is an oral growth-hormone secretagogue with human data in older adults, ibutamoren is the molecule those papers used. If the question is a short, selective pulse at GHS-R1a that a bench can turn off in an hour, that is ipamorelin, and the 1998 tables are why. If the question is the other door on the same cell, that is a GHRH analogue, CJC without DAC or tesamorelin. Stacking the long oral with a short peptide does not create a third receptor. It stacks a day-long ghrelin signal on top of whatever pulse you already provoked, and the hunger and the glucose come with the long one. Somatropin, the hormone itself, skips both doors. People who want the oral because they dislike needles are allowed that preference. They should still know they bought a different clock, not a more convenient ipamorelin.

In short. MK-677 is the oral, day-long ghrelin mimetic. Ipamorelin is the short selective peptide. CJC is the other receptor. Convenient is not the same molecule.